葛根素注射液联合盐酸法舒地尔治疗缺血性脑梗死的临床研究

目的探究葛根素注射液联合盐酸法舒地尔治疗缺血性脑梗死的临床疗效。方法选取2014年6月—2015年6月广州市花都区花山镇卫生院收治的缺血性脑梗死患者84例,按照治疗方法的不同分为对照组和治疗组,每组各42例。对照组静脉滴注盐酸法舒地尔注射液,60 mg加入到250 m L生理盐水中,1次/d。治疗组在对照组治疗的基础上静脉滴注葛根素注射液,400 mg加入生理盐水250 m L,1次/d。两组患者均连续治疗14 d。观察两组的临床疗效,同时比较两组治疗前后红细胞沉降率(ESR)、血细胞比容(HCT)、纤维蛋白原(FIB)、红细胞聚集指数(RF)、全血高切黏度(HS)、神经功能缺损(NIHSS)评分、血管内皮素-1(ET-1)的变化情况。比较两组不良反应发生情况。结果治疗后,对照组和治疗组的总有效率分别为80.95%、95.24%,两组比较差异具有统计学意义(P0.05)。治疗后,两组ESR、HCT、FIB、RF、HS、NIHSS评分、ET-1均较治疗前显著降低,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的降低程度优于对照组,两组比较差异有统计学意义(P0.05)。对照组和治疗组的不良反应发生率分别为9.52%、7.14%;两组比较差异无统计学意义。结论葛根素注射液联合盐酸法舒地尔治疗缺血性脑梗死具有较好的临床疗效,能够明显改善患者的血液流变学状态,并能显著降低ET-1的表达,具有一定的临床推广应用价值。

Clinical study on Puterarin Injection combined with fasudil hydrochloride in treatment of ischemic cerebral infarction

Objective To investigate the clinical effect of Puterarin Injection combined with fasudil hydrochloride in treatment of ischemic cerebral infarction.Methods Patients (84 cases) with ischemic cerebral infarction in Huashan Township Health Center of Huadu District in Guangzhou from June 2014 to June 2015 were enrolled in this study. According to the different treatment plans, patients were divided into control group (42 cases) and treatment group (42 cases). The patients in the control group were iv administered with Fasudil Hydrochloride Injection, 60 mg added into normal saline 250 mL, once daily. The patients in the treatment group were ivadministered with Puterarin Injection on the basis of control group, 400 mg added into normal saline 250 mL, once daily. The patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the changes of ESR, HCT, FIB, RF, HS, NIHSS scores, and ET-1 in two groups before and after treatment were compared. The adverse reactions in two groups were compared.Results After treatment, the efficacies in the control and treatment groups were 80.95 and 95.24%, respectively, and there were differences between two groups (P < 0.05). After treatment, ESR, HCT, FIB, RF, HS, NIHSS scores, and ET-1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The incidence of adverse reactions in the control and treatment groups were 9.52% and 7.14%, respectively, and there was no difference between two groups.Conclusion Puterarin Injection combined with fasudil hydrochloride has clinical curative effect in treatment of ischemic cerebral infarction, and can significantly improve hemorheology status, and can significantly reduce the expression of ET-1, which has a certain clinical application value.